Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. · 2018

Read Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). by Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5956851.txt.

Introduction

Chae and co-authors review dual blockade of CTLA4 and PD-1 or PD-L1 in cancer immunotherapy. Their review appeared in the Journal for Immunotherapy of Cancer. Checkpoint inhibitors have won many approvals across cancers. Preclinical work hinted that pairs could beat single agents. Early trials showed clear survival gains for the combination. Nivolumab plus ipilimumab gained approval for advanced melanoma.

The review draws lessons from trials in melanoma and lung cancer. It covers non-small cell lung cancer in depth. Dual blockade is now being tested across many tumour types. Trials also pair it with chemotherapy, surgery, and radiation. The authors sketch prospects for wider use.

Catalog record

CREATORChae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE101 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5956851

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) By Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R. Cruz, Sunandana Chandra, Jaehyuk Choi, Francis Giles Published in: Journal for Immunotherapy of Cancer DOI: 10.1186/s40425-018-0349-3 ABSTRACT Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. BACKGROUND The regulation of immune responses through MoAbs is a ground-breaking therapeutic strategy in oncology. Based on substantial pre-clinical and clinical evidence, several immunotherapy agents have received approval by the FDA as standard of care treatment for various malignancies over the past two decades [1, 2]. However, with increasing experience in the use of immunotherapy agents in clinical settings, several limitations, such as treatment resistance and undesired immunogenicity, have been observed [3, 4]. Extensive efforts have been made to meet such challenges, and novel immune checkpoints are being tested and are expected to pave the way for the next generation of immunotherapy agents [5]. The fundamental goal in advancing anti-cancer immunotherapy is to improve clinical outcomes. The use of combination checkpoint inhibition is being applied to meet this goal. This approach intends to exploit the distinct mechanisms of immunomodulation of two MoAbs in a single treatment regimen. Recent evidence suggests that the combined use of an anti-CTLA-4 immune-checkpoint inhibitor with an anti-PD-1/PD-L1 MoAb may have complementary action, thus yielding a higher clinical efficacy than either agent individually [6, 7]. Comprehensive data on the efficacy of MoAb combination therapy in clinical settings is warranted in order to ascertain the true therapeutic value of this treatment strategy. Presently, combination checkpoint inhibition is being extensively evaluated for potential clinical benefit in a large number of tumor histologies. Due to positive outcomes in preliminary trials, nivolumab (IgG4 anti-PD-1 MoAb) plus ipilimumab (fully humanized IgG1 anti-CTLA-4 MoAb) is one of the most enthusiastically investigated combined immunotherapy regimens, with over 100 clinical trials in various stages [8, 9]. Of note, nivolumab plus ipilimumab received approval for use in BRAF V600 wild-type metastatic/unresectable melanoma, making it the first combination checkpoint inhibition regimen to be approved by the FDA [9]. In addition, other PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination checkpoint inhibition regimens that are presently in clinical trials include atezolizumab (anti-PD-L1 MoAb) plus ipilimumab, pembrolizumab (IgG4 anti-PD-1 MoAb) plus ipilimumab, and tremelimumab (IgG2 anti-CTLA-4 MoAb) plus durvalumab (Fc optimized anti-PD-L1 MoAb) [10]. The data published from these trials will be crucial to appraise the efficacy of combination immune checkpoint inhibitor regimens in varying clinical scenarios. In this review, we describe the rationale for combined immunotherapy with PD-1/PD-L1 plus CTLA-4 checkpoint inhibitors. Building on what we have learned through studies of combination checkpoint inhibition in patients with melanoma and NSCLC, we shall also critically assess the current landscape and future prospects for the development of an ideal combination checkpoint inhibition regimen. Role of PD-1/PD-L1 and CTLA-4 in modulation of anti-tumor T-cell activity The process of T cell activation requires two signals. The primary signal comes from the binding of the T cell receptor (TCR) to the major histocompatibility complex (MHC) molecule presented by an antigen presenting cell (APC) [11]. The costimulatory signal may arise from one of several distinct T cell-APC interactions. One such pathway is the engagement of CD28 on T cells with CD80 (B7–1) or CD86 (B7–2) on APCs [11] (Fig. 1). T-cell activity can be modulated by regulating the generation of costimulatory signals through various mechanisms.Fig. 1Mechanism of CTLA 4 and PD-1/PD-L1 inhibition. The activation of T cells is mediated by the interaction of T cell receptor and the CD28 receptor with class II major histocompatibility complex and B7 co-stimulatory molecule located on the antigen presenting cells. The interaction of CTLA-4 with the B7 molecule delivers an inhibitory signal, effectively checked by CTLA-4 inhibitors. On the other hand, the negative regulation of T cells resulting from PD-1/PD-L1 interaction between T cells and tumor cells is prevented by PD-1/PD-L1 inhibitors. Abbreviations: APC, antigen presenting cell; PD-1, programmed death receptor-1; PD-L1, programmed cell death receptor ligand-1; TCR, T cell receptor; MHC I, major histocompatibility complex class I; MHC II, major histocompatibility complex class II Several signaling pathways have been implicated in the modulation of T cell activity. The CTLA-4 molecule is a homolog of CD28 and is expressed by T cells (Fig. 1) [12, 13]. The influence of CTLA-4 on T cell activity primarily occurs in the priming phase of T cell activation [14]. CTLA-4 competitively binds to B7 on APCs and inhibits the costimulatory signal that arises from the engagement of CD28 with B7, thereby diminishing the T cell immune response [13, 15–18]. The upregulation of CTLA-4 expression on CD8+ and CD4+ T cells precludes stimulatory signaling from CD28-B7 binding and TCR-MHC binding [11, 19]. On the other hand, regulatory T cells (Treg cells) exhibit constitutive expression of CTLA-4 [20]. Murine models bearing Treg cells deficient in CTLA-4 exhibited attenuated immunosuppressive activity, thus highlighting the significance of CTLA-4 in regulating immunological self-tolerance [20]. The PD-1 molecule is akin to CTLA-4. It is a member of the B7-CD28 family and is expressed by myeloid derived cells, B cells, and T cells [21, 22]. PD-1 has two corresponding ligands, PD-L1 and PD-L2 [14]. PD-L1 is expressed by a diverse set of cells including hematopoietic cells, leucocytes, parenchymal cells, and tumor cells, whereas PD-L2 is expressed by dendritic cells and macrophages [22–24]. The PD-1 receptor on T cells binds PD-L1 expressed by APCs and inhibits pro-inflammatory events such as T cell proliferation and cytokine production (Fig. 1) [14, 25]. Of note, recent evidence has suggested that PD-1/PD-L1 interactions facilitate immune escape by tumor cells [24, 26]. This phenomenon has been attributed to PD-1/PD-L1 mediated induction of anergy and apoptosis of activated T cells, tumor resistance to the cytotoxic T cell response, and differentiation of CD4+ T cells into Fox3p + CD4+ Treg cells [27–29]. An intricate knowledge of various

Read the complete text